Analgesic use may decrease postmenopausal estrogen levels

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Postmenopausal women who regularly use painkillers have lower estrogen levels, which could lead to a decreased risk of breast or ovarian cancer.

Postmenopausal women who regularly use painkillers have lower estrogen levels, which could lead to a decreased risk of breast or ovarian cancer, according to researchers at Boston's Brigham and Women's Hospital and Harvard Medical School (Cancer Epidemiol Biomarkers Prev online, March 23, 2010).

The investigators looked at the link between the use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and concentrations of estrogens and androgens among 740 postmenopausal women who participated in the Nurses' Health Study. The frequency of all analgesic use was inversely associated with estradiol, free estradiol, estrone sulfate, and the ratio of estradiol to testosterone. The average estradiol levels were 10.5% lower among women who regularly used aspirin or non-aspirin NSAIDs. Free estradiol levels were 10.6% lower and estrone sulfate levels were 11.1% lower among regular users of aspirin.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content